Mer­ck’s PhI­II liv­er can­cer study for Keytru­da fails on two key end­points, just three months af­ter the FDA gave it the green light

In a rare set­back, Mer­ck has suf­fered a key Phase III fail­ure for Keytru­da that could put a crimp in its sales prospects.

The phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.